Resultado de búsqueda
The Viral Hepatitis National Progress Report provides information on progress in the implementation of recommended interventions and the impact these interventions are having on prevention of viral hepatitis transmission, disease, and associated mortality.
- Overview
Reduce reported rate ‡ of hepatitis B-related deaths among...
- 2023 National Viral Hepatitis Progress Report
Reduce reported rate ‡ of hepatitis B-related deaths among...
- Overview
3 de abr. de 2024 · During 2022, rates of acute hepatitis C were highest among males, persons aged 30–39 years, non-Hispanic American Indian/Alaska Native (AI/AN) persons, and those living in the Eastern and Southeastern states. Among cases with risk information reported, the most common was injection drug use.
Regional and global estimates of HCV prevalence, cascade of care, and disease burden were calculated based on 235 countries and territories. Findings: Models were built for 110 countries or territories: 83 were approved by local experts and 27 were based on published data alone.
- Key Facts
- Overview
- Geographical Distribution
- Transmission
- Symptoms
- Testing and Diagnosis
- Treatment
- Service Delivery
- Prevention
- Who Response
Hepatitis C is an inflammation of the liver caused by the hepatitis C virus.The virus can cause both acute and chronic hepatitis, ranging in severity from a mild illness to a serious, lifelong illness including liver cirrhosis and cancer.The hepatitis C virus is a bloodborne virus and most infection occur through exposure to blood from unsafe injection practices, unsafe health care, unscreened blood transfusions, injection drug use...Globally, an estimated 50 million people have chronic hepatitis C virus infection, with about 1.0 million new infections occurring per year.Hepatitis C is a viral infection that affects the liver. It can cause both acute (short term) and chronic (long term) illness. It can be life-threatening. Hepatitis C is spread through contact with infected blood. This can happen through sharing needles or syringes, or from unsafe medical procedures such as blood transfusions with unscreened blood ...
Hepatitis C virus infection occurs in all WHO regions. The highest burden of disease is in the Eastern Mediterranean Region with 12 million people chronically infected. In the South-East Asia Region (9 million), European Region (9 million) and the Western Pacific Region (7 million) people are chronically infected. Eight million people are chronical...
The hepatitis C virus is a bloodborne virus. It is most commonly transmitted through: 1. the reuse or inadequate sterilization of medical equipment, especially syringes and needles in healthcare settings; 2. the transfusion of unscreened blood and blood products; and 3. injecting drug use through the sharing of injection equipment. HCV can be passe...
Most people do not have symptoms in the first weeks after infection. It can take between two weeks and six months to have symptoms. When symptoms do appear, they may include: 1. fever 2. feeling very tired 3. loss of appetite 4. nausea and vomiting 5. abdominal page 6. dark urine 7. pale faeces 8. joint pain 9. jaundice (yellowing of the skin or ey...
Because new HCV infections are usually asymptomatic, few people are diagnosed when the infection is recent. In those people who develop chronic HCV infection, the infection is often undiagnosed because it remains asymptomatic until decades after infection when symptoms develop secondary to serious liver damage. HCV infection is diagnosed in 2 steps...
There are effective treatments for hepatitis C. The goal of treatment is to cure the disease and prevent long-term liver damage. Antiviral medications, including sofosbuvir and daclatasvir, are used to treat hepatitis C. Some people's immune system can fight the infection on their own and new infections do not always need treatment. Treatment is al...
Until recently, delivery of hepatitis C testing and treatment in many countries relied on specialist-led (usually by a hepatologist or gastroenterologist) care models in hospital settings to administer complex treatment. With the short-course oral, curative pangenotypic HCV DAA treatment regimens with few if any side-effects, minimal expertise and ...
There is no effective vaccine against hepatitis C. The best way to prevent the disease is to avoid contact with the virus. Extra care should be used in healthcare settings and for people with a higher risk of hepatitis C virus infection. People at higher risk include those who inject drugs, men who have sex with men, and those living with HIV. Ways...
Global health sector strategies on, respectively, HIV, viral hepatitis, and sexually transmitted infections for the period 2022–2030 (GHSSs)guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS, viral hepatitis (especially chronic hepatitis B and C) and sexually transmitted infections by 2030. T...
In 2022, 23 273 cases of hepatitis C were reported in 29 EU/EEA countries. Excluding countries that only reported acute cases, 23 249 cases were notified, corresponding to a crude rate of 6.2 cases per 100 000 population. Of the cases reported, 6% were acute, 34% chronic, and 57% were unknown.
15 de feb. de 2022 · In the past decade, a number of global estimates of hepatitis C virus (HCV) prevalence have been published by our group, including global prevalence assessments (published in 2014 and 2016), paediatric prevalence (2020), and prevalence among women of childbearing age (2021).
Hepatitis C virus (HCV) is a hepatotropic RNA virus that can cause acute and chronic hepatitis, with progressive liver damage resulting in cirrhosis, decompensated liver disease, and hepatocellular carcinoma. In 2016, WHO called for the elimination of HCV infection as a public health threat by 2030.
